Sökning: "olle stål"
Visar resultat 11 - 15 av 18 avhandlingar innehållade orden olle stål.
11. Homeobox B13 in breast cancer : Prediction of tamoxifen benefit
Sammanfattning : A major issue in the management of breast cancer is to identify patients who are less likely to be cured after primary treatment and would benefit from adjuvant chemotherapy. Of great importance is also identification of patients with only local disease who traditionally would be given chemotherapy but would survive without. LÄS MER
12. Clinical potential of the mTOR effectors S6K1, S6K2 and 4EBP1 in breast cancer
Sammanfattning : The prognosis of patients diagnosed with breast cancer has been considerably improved in the latest 25 years, as a result of continuous development of diagnostics and treatment regimens. Though, tumour diseases, for woman mainly lung cancer and breast cancer, still constitute of the most common causes of death in developed countries, following heart diseases. LÄS MER
13. Biomarkers In Brain Tumors With Focus On Glioblastoma
Sammanfattning : The primary brain tumors, gliomas, are not very common but they are deadly. Each year in Sweden around 500 patients will be diagnosed with a glioma and unfortunately most of them will have the most aggressive type, glioblastoma (GBM). Median survival, even if treated, is poor (14-17 months). LÄS MER
14. Alterations in the PI3K/AKT Signaling Pathway and Response to Adjuvant Treatment in Breast Cancer
Sammanfattning : (PI3K)/AKT signaling pathway could be a cause of therapeutic resistance in breast cancer. The PI3K/AKT pathway controls cell proliferation, cell growth and survival, and its members include oncogenes and tumor suppressor genes. Alterations in this pathway are frequent in cancer. LÄS MER
15. Long-term effects of adjuvant tamoxifen treatment on cardiovascular disease and cancer
Sammanfattning : The aims of this thesis were to investigate the long-term effects of adjuvant tamoxifen treatment on breast cancer recurrence and mortality, cardiovascular disease, and the incidence of secondary cancer.Between 1982 and 1992, postmenopausal patients with early stage breast cancer were included in a randomized clinical study of 2 or 5 years of postoperative tamoxifen therapy. LÄS MER